OBJECTIVE: : To evaluate the effects on monthly @entity548 of four different progestogens administered in association with transdermal @entity53 in a continuous sequential @entity172 -progestin therapy (CS-EPT). DESIGN: : This prospective, open, randomized, clinical trial included 100 healthy postmenopausal @entity1 . @entity1 were randomized into four treatment groups, each consisting of 25 @entity1 . Treatment consisted of 50 mug/day transdermal @entity53 for all @entity1 combined to receive four different @entity7828 (group A: @entity11796 , 10 mg/day; group B: @entity42837 , 5 mg/day; group C: @entity21909 , 10 mg/day; group D: micronized @entity1420 , 200 mg/day) per os from the 14th to 25th day of each 28-day cycle. The duration of treatment was 12 cycles. @entity1 were asked to record in a daily diary the occurrence of any @entity3556 , the days of application of each patch, the days of assumption of the different progestogens, and the exact moment of @entity548 onset. RESULTS: : A total of 937 cycles could be evaluated. In 690 cycles (73.6%), regular progestogen-related @entity548 was reported. Among the other cycles, we observed 73 episodes of @entity2588 (7.8%, each one lasting one cycle), 78 episodes of @entity548 (8.3%), and 96 episodes of @entity1867 (10.2%). @entity1 receiving @entity42837 had a significantly higher incidence of regular progestogen-associated @entity548 in comparison with those receiving @entity11796 or natural @entity1420 , and @entity1 receiving @entity21909 had a significantly higher incidence of regular progestogen-associated @entity548 in comparison with those receiving natural @entity1420 . CONCLUSION: : Our data suggest that CS-EPT generally leads to regular withdrawal @entity548 in @entity1 without uterine pathology. Micronized @entity1420 seems to induce more @entity548 episodes.

Bleeding patterns during continuous XXXX with different sequential progestogens therapy.

@entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients'] @entity3556 :: ('MESH:D014592', 'Disease') :: ['vaginal bleeding'] @entity11796 :: ('MESH:D017258', 'Chemical') :: ['medroxyprogesterone acetate'] @entity548 :: ('MESH:D006470', 'Disease') :: ['irregular bleeding', 'bleeding'] @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone'] @entity7828 :: ('MESH:D011372', 'Chemical') :: ['progestogens'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['17beta-estradiol', 'estradiol'] @entity42837 :: ('MESH:C038501', 'Chemical') :: ['nomegestrol acetate'] @entity1867 :: ('MESH:D008796', 'Disease') :: ['spotting'] @entity2588 :: ('MESH:D000568', 'Disease') :: ['amenorrhea'] @entity21909 :: ('MESH:D004394', 'Chemical') :: ['dydrogesterone']
@entity53 :: (MESH:D004958,Chemical) :: ['estradiol']
